Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuke Hongjindan Capsule is a Traditional Chinese Medicine (TCM) developed by Hunan Jiudian Pharmaceutical for the treatment of chronic pelvic pain associated with the sequelae of pelvic inflammatory disease (SPID). It is specifically indicated for patients presenting with the damp-heat and blood stasis syndrome (湿热瘀阻证). The drug is currently in Phase III clinical trials in China to evaluate its efficacy and safety in reducing pain and improving clinical symptoms in this patient population. As a TCM formulation, it likely utilizes a multi-component approach to clear heat, resolve dampness, and promote blood circulation to alleviate inflammation and pain in the pelvic cavity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuke Hongjindan Capsule.